Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study

Core Viewpoint - Regeneron's experimental therapy demonstrated either a complete or partial disappearance of a precancerous disorder in all patients during a mid-stage trial, which is significant as this disorder can lead to blood cancer [1] Group 1 - The therapy showed promising results in a mid-stage trial, indicating its potential effectiveness in treating precancerous conditions [1] - All patients in the trial experienced either complete or partial disappearance of the disorder, highlighting the therapy's efficacy [1]